Treatment of Acute Myelogenous Leukemia in Children and Adults

Authors:
  • HWHoward J. Weinstein
    Howard J. Weinstein
  • RMRobert J. Mayer
    Robert J. Mayer
  • DRDavid S. Rosenthal
    David S. Rosenthal
  • BCBruce M. Camitta
    Bruce M. Camitta
  • FCFelice S. Coral
    Felice S. Coral
  • DNDavid G. Nathan
    David G. Nathan
  • EFEmil Frei
    Emil Frei
Publisher website
Google Scholar
Abstract
We designed a protocol to address the problem of relapse from complete remission in acute myelogenous leukemia. Patients in remission were treated for 14 months; early and later intensification of chemotherapy, sequential drug combinations, and high-dose continuous infusions of cytarabine were included. Eighty-three consecutive patients under 50 years of age were entered into this study from February 1976 to October 1979. The rate of complete remission is 70 per cent. A Kaplan–Meier analysis predicts that 49±17 per cent of patients (mean ±2 S.D.) who entered complete remission will remain free of disease at two years. Durations of complete remission for patients in the 0 to 17-year and 18 to 50-year age groups are comparable. (N Engl J Med. 1980; 303:473–8.)

This publication has 27 references indexed in Scilit: